◎ Sugi Atlas

Atlas / Disease / Cutaneous leishmaniasis

Cutaneous leishmaniasis

disease
On this page

Also known as Asian desert cutaneous leishmaniasiszone of skin leishmaniasis

Summary

Cutaneous leishmaniasis (MONDO:0005446) is a disease with 15 cohort genes (14 GWAS associations across 1 studies) and 52 clinical trials. Top therapeutic interventions include paromomycin, miltefosine, and sodium stibogluconate.

At a glance

  • Cohort genes: 15
  • GWAS associations: 14
  • Clinical trials: 52

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecutaneous leishmaniasis
Mondo IDMONDO:0005446
EFOEFO:0005046
MeSHD016773
DOIDDOID:9111
ICD-10-CMB55.1
ICD-11124737785
NCITC34768, C34770
SNOMED CT186807008
UMLSC0023283
MedGen9715
GARD0024189
Anatomy (UBERON)UBERON:0000014
Is cancer (heuristic)no

Also known as: Asian desert cutaneous leishmaniasis · zone of skin leishmaniasis

Data availability: 14 GWAS associations (1 study).

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › leishmaniasis › cutaneous leishmaniasis

Related subtypes (2): visceral leishmaniasis, mucocutaneous leishmaniasis

Subtypes (1): leishmaniasis, diffuse cutaneous

Genetics & variants

GWAS landscape

14 GWAS associations across 1 studies. Top hits map to 13 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs132616181e-06PXDNLA0.87
rs13830862e-06ZNF385DT0.85
rs80843062e-06SERPINB10C1.07
rs775631422e-06TSPAN9 - LINC02827G1.28
rs49398532e-06DYMG1.09
rs12396272053e-06CHKBG1.09
rs1435869683e-06CALCRT1.16
rs38486105e-06PPP6R1T0.84
rs752706135e-06CRLF3T0.83
rs80904186e-06TCF4T0.91
rs1444881346e-06STX7A0.82
rs742855587e-06LAMP3T0.87
rs107834967e-06LINC00592A1.06
rs2015552019e-06S100BTAGATGTTAAAA1.06

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST011739Castellucci LC20202,0662,046A Genome-Wide Association Study Identifies SERPINB10, CRLF3, STX7, LAMP3, IFNG-AS1 and KRT80 As Risk Loci Contributing to Cutaneous Leishmaniasis In Brazil.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory1
Tier 4: intronic/intergenic13

MAF distribution

BucketVariants
common (>=0.05)10
low_freq (0.01-0.05)0
rare (<0.01)0
unknown4

Functional consequences

ConsequenceCount
intron_variant12
intergenic_variant1
regulatory_region_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs13261618851716260G>A0.05intron_variantPXDNL1e-06Tier 4: intronic/intergenic
rs1383086322076244A>G,T0.05intron_variantZNF385D2e-06Tier 4: intronic/intergenic
rs80843061863931529T>C0.05intron_variantSERPINB102e-06Tier 4: intronic/intergenic
rs77563142123288238A>G,Tintergenic_variantTSPAN9 - LINC028272e-06Tier 4: intronic/intergenic
rs49398531849239784A>G,T0.05intron_variantDYM2e-06Tier 4: intronic/intergenic
rs12396272052250600379GCGCGGCGGCGCAGCTCCCGGGGCCGCCCCGGCCTCT>Gregulatory_region_variantCHKB3e-06Tier 3: regulatory
rs143586968793435767C>T0.05intron_variantCALCR3e-06Tier 4: intronic/intergenic
rs38486101955250857T>A,C0.05intron_variantPPP6R15e-06Tier 4: intronic/intergenic
rs752706131730809108C>T0.05intron_variantCRLF35e-06Tier 4: intronic/intergenic
rs80904181855288444C>T0.05intron_variantTCF46e-06Tier 4: intronic/intergenic
rs1444881346132494423C>Aintron_variantSTX76e-06Tier 4: intronic/intergenic
rs742855583183139473C>A,T0.05intron_variantLAMP37e-06Tier 4: intronic/intergenic
rs107834961252196220A>C,G0.05intron_variantLINC005927e-06Tier 4: intronic/intergenic
rs2015552012146603727T>Aintron_variantS100B9e-06Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TCF4Orphanet:171Primary sclerosing cholangitis
TCF4Orphanet:178469Autosomal dominant non-syndromic intellectual disability
TCF4Orphanet:2896Pitt-Hopkins syndrome
TCF4Orphanet:98974Fuchs endothelial corneal dystrophy
CHKBOrphanet:280671Megaconial congenital muscular dystrophy
CHKBOrphanet:521305Proximal myopathy with focal depletion of mitochondria
DYMOrphanet:178355Smith-McCort dysplasia
DYMOrphanet:239Dyggve-Melchior-Clausen disease

Cohort genes → proteins

15 cohort genes, 15 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only15

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
S100BHGNC:10500ENSG00000160307P04271Protein S100-Bgwas
STX7HGNC:11442ENSG00000079950O15400Syntaxin-7gwas
TCF4HGNC:11634ENSG00000196628P15884Transcription factor 4gwas
CALCRHGNC:1440ENSG00000004948P30988Calcitonin receptorgwas
LAMP3HGNC:14582ENSG00000078081Q9UQV4Lysosome-associated membrane glycoprotein 3gwas
CRLF3HGNC:17177ENSG00000176390Q8IUI8Cytokine receptor-like factor 3gwas
CHKBHGNC:1938ENSG00000100288Q9Y259Choline/ethanolamine kinasegwas
DYMHGNC:21317ENSG00000141627Q7RTS9Dymeclingwas
TSPAN9HGNC:21640ENSG00000011105O75954Tetraspanin-9gwas
ZNF385DHGNC:26191ENSG00000151789Q9H6B1Zinc finger protein 385Dgwas
PXDNLHGNC:26359ENSG00000147485A1KZ92Probable oxidoreductase PXDNLgwas
KRT80HGNC:27056ENSG00000167767Q6KB66Keratin, type II cytoskeletal 80gwas
PPP6R1HGNC:29195ENSG00000105063Q9UPN7Serine/threonine-protein phosphatase 6 regulatory subunit 1gwas
MAPK8IP2HGNC:6883ENSG00000008735Q13387C-Jun-amino-terminal kinase-interacting protein 2gwas
SERPINB10HGNC:8942ENSG00000242550P48595Serpin B10gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
S100BProtein S100-BSmall zinc- and- and calcium-binding protein that is highly expressed in astrocytes and constitutes one of the most abundant soluble proteins in brain.
STX7Syntaxin-7May be involved in protein trafficking from the plasma membrane to the early endosome (EE) as well as in homotypic fusion of endocytic organelles.
TCF4Transcription factor 4Transcription factor that binds to the immunoglobulin enhancer Mu-E5/KE5-motif.
CALCRCalcitonin receptorG protein-coupled receptor activated by ligand peptides amylin (IAPP), calcitonin (CT/CALCA) and calcitonin gene-related peptide type 1 (CGRP1/CALCA).
LAMP3Lysosome-associated membrane glycoprotein 3Lysosomal membrane glycoprotein which plays a role in the unfolded protein response (UPR) that contributes to protein degradation and cell survival during proteasomal dysfunction.
CRLF3Cytokine receptor-like factor 3May play a role in the negative regulation of cell cycle progression.
CHKBCholine/ethanolamine kinaseHas a key role in phospholipid metabolism, and catalyzes the first step of phosphatidylethanolamine and phosphatidylcholine biosynthesis.
DYMDymeclinNecessary for correct organization of Golgi apparatus.
PXDNLProbable oxidoreductase PXDNLProbable oxidoreductase.
PPP6R1Serine/threonine-protein phosphatase 6 regulatory subunit 1Regulatory subunit of protein phosphatase 6 (PP6).
MAPK8IP2C-Jun-amino-terminal kinase-interacting protein 2The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module.
SERPINB10Serpin B10Protease inhibitor that may play a role in the regulation of protease activities during hematopoiesis and apoptosis induced by TNF.

Protein-family classification

Druggable: 4 · Difficult: 3 · Unknown: 8 · Druggable fraction: 0.27

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Antibody/Immunoglobulin23.9×0.550
Kinase11.9×0.677
GPCR11.6×0.677
Scaffold/PPI11.1×0.677
Transcription factor21.1×0.677
Other/Unknown81.0×0.677

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
S100BOther/UnknownnoS100/CaBP7/8-like_CS, EF_hand_dom, EF-hand-dom_pair
STX7Other/UnknownnoT_SNARE_dom, Syntaxin_N, Syntaxin/epimorphin_CS
TCF4Transcription factorno7.6.2.3bHLH_dom, HLH_DNA-bd_sf, NeuroDiff_E-box_TFs
CALCRGPCRyesGPCR_2_secretin-like, GPCR_2_calcitonin_rcpt, GPCR_2_extracellular_dom
LAMP3Other/UnknownnoLysosome-assoc_membr_glycop, Lamp2-like_luminal
CRLF3Antibody/ImmunoglobulinyesFN3_dom, Ig-like_fold, FN3_sf
CHKBKinaseyes2.7.1.32Kinase-like_dom_sf
DYMOther/UnknownnoDymeclin
TSPAN9Other/UnknownnoTetraspanin_animals, Tetraspanin_EC2_sf, Tetraspanin/Peripherin
ZNF385DTranscription factornoMatrin/U1-like-C_Znf_C2H2, Znf_C2H2_type, Znf_C2H2_sf
PXDNLAntibody/Immunoglobulinyes1.11.1.7Cys-rich_flank_reg_C, VWF_dom, Leu-rich_rpt
KRT80Other/UnknownnoKeratin_II, IF_rod_dom
PPP6R1Other/UnknownnoSAPS, ARM-type_fold
MAPK8IP2Scaffold/PPInoSH3_domain, PTB/PI_dom, PH-like_dom_sf
SERPINB10Other/UnknownnoSerpin_fam, Serpin_CS, Serpin_dom

Expression context

Cohort genes with no expression data: 0.

15 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)15
unknown0

Top tissues across cohort

TissueCohort genes
endothelial cell2
granulocyte2
bone marrow cell2
apex of heart2
cerebellar hemisphere2
C1 segment of cervical spinal cord1
inferior vagus X ganglion1
olfactory bulb1
cortical plate1
monocyte1
pericardium1
skin of hip1
endometrium epithelium1
hair follicle1
tibia1
lower lobe of lung1
sperm1
visceral pleura1
leukocyte1
mononuclear cell1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
S100B230broadmarkerC1 segment of cervical spinal cord, inferior vagus X ganglion, olfactory bulb
STX7293ubiquitousmarkercortical plate, endothelial cell, monocyte
TCF4292ubiquitousmarkerendothelial cell, skin of hip, pericardium
CALCR71tissue_specificmarkertibia, endometrium epithelium, hair follicle
LAMP3199broadmarkerlower lobe of lung, sperm, visceral pleura
CRLF3287ubiquitousmarkertrabecular bone tissue, mononuclear cell, leukocyte
CHKB134ubiquitousmarkerpituitary gland, granulocyte, adenohypophysis
DYM254ubiquitousmarkerbone marrow cell, embryo, ganglionic eminence
TSPAN9270ubiquitousmarkerapex of heart, cerebellar hemisphere, cerebellar cortex
ZNF385D221broadmarkerdescending thoracic aorta, ascending aorta, thoracic aorta
PXDNL134tissue_specificmarkercardiac muscle of right atrium, cardiac atrium, apex of heart
KRT80170broadmarkerskin of abdomen, upper arm skin, skin of leg
PPP6R1134ubiquitousmarkerleft testis, right testis, granulocyte
MAPK8IP2204broadmarkerBrodmann (1909) area 10, right hemisphere of cerebellum, cerebellar hemisphere
SERPINB1088broadmarkerbone marrow, bone marrow cell, type B pancreatic cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PXDNL9,051
TCF43,342
S100B3,175
STX73,037
MAPK8IP21,849
PPP6R11,716
LAMP31,527
CALCR1,390
DYM1,298
CHKB1,154

Structural data

PDB: 6 · AlphaFold-only: 9 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
CALCRP3098832
S100BP0427115
TCF4P158845
CHKBQ9Y2593
LAMP3Q9UQV41
MAPK8IP2Q133871

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
CRLF3Q8IUI890.15
TSPAN9O7595489.65
SERPINB10P4859588.99
DYMQ7RTS987.91
PXDNLA1KZ9281.78
STX7O1540078.96
KRT80Q6KB6676.93
PPP6R1Q9UPN767.96
ZNF385DQ9H6B162.68

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 49. Enrichment computed across 15 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Calcitonin-like ligand receptors1148.3×0.069CALCR
Synthesis of PE1125.5×0.069CHKB
Advanced glycosylation endproduct receptor signaling1102.0×0.069S100B
TRAF6 mediated NF-kB activation165.3×0.069S100B
TGFBR3 expression165.3×0.069TCF4
Synthesis of PC158.3×0.069CHKB
Myogenesis154.4×0.069TCF4
Signaling by TGFBR3152.6×0.069TCF4
Nuclear signaling by ERBB4149.4×0.069S100B
TAK1-dependent IKK and NF-kappa-B activation142.9×0.069S100B
Signaling by ERBB4138.8×0.069S100B
Interleukin-1 family signaling138.8×0.069S100B
DDX58/IFIH1-mediated induction of interferon-alpha/beta136.2×0.069S100B
Toll Like Receptor 10 (TLR10) Cascade130.8×0.069S100B
Toll Like Receptor 5 (TLR5) Cascade130.8×0.069S100B
MyD88 cascade initiated on plasma membrane129.1×0.069S100B
Toll Like Receptor 3 (TLR3) Cascade127.6×0.069S100B
Class B/2 (Secretin family receptors)127.2×0.069CALCR
TRIF (TICAM1)-mediated TLR4 signaling127.2×0.069S100B
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation127.2×0.069S100B
MyD88 dependent cascade initiated on endosome127.2×0.069S100B
MyD88-independent TLR4 cascade126.3×0.069S100B
Toll Like Receptor 7/8 (TLR7/8) Cascade126.3×0.069S100B
Toll Like Receptor 9 (TLR9) Cascade125.1×0.069S100B
Toll Like Receptor TLR6:TLR2 Cascade125.1×0.069S100B
Toll Like Receptor 2 (TLR2) Cascade124.7×0.069S100B
Toll Like Receptor TLR1:TLR2 Cascade124.0×0.069S100B
COPII-mediated vesicle transport123.3×0.069PPP6R1
Innate Immune System27.3×0.069S100B, SERPINB10
Signal Transduction34.4×0.069S100B, TCF4, CALCR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 13 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
nonassociative learning11296.3×0.018MAPK8IP2
receptor diffusion trapping11296.3×0.018TSPAN9
regulation of viral life cycle11296.3×0.018LAMP3
response to glucocorticoid249.9×0.018S100B, CALCR
calcitonin family receptor signaling pathway1648.1×0.020CALCR
negative regulation of skeletal muscle cell differentiation1648.1×0.020S100B
protein-DNA complex assembly1432.1×0.020TCF4
organelle localization1324.1×0.020STX7
amylin receptor 3 signaling pathway1324.1×0.020CALCR
positive regulation of receptor localization to synapse1324.1×0.020STX7
CDP-choline pathway1259.3×0.020CHKB
system development1259.3×0.020PXDNL
amylin receptor signaling pathway1259.3×0.020CALCR
amylin receptor 1 signaling pathway1259.3×0.020CALCR
amylin receptor 2 signaling pathway1259.3×0.020CALCR
mating behavior1216.1×0.020MAPK8IP2
organelle assembly1216.1×0.020STX7
response to anesthetic1216.1×0.020S100B
sympathetic neuron projection extension1216.1×0.020S100B
mitocytosis1216.1×0.020TSPAN9
calcitonin gene-related peptide receptor signaling pathway1216.1×0.020CALCR
positive regulation of neuron differentiation230.5×0.020S100B, TCF4
response to methylmercury1185.2×0.022S100B
signal complex assembly1162.0×0.023MAPK8IP2
modulation of excitatory postsynaptic potential1162.0×0.023MAPK8IP2
phosphatidylethanolamine biosynthetic process1144.0×0.023CHKB
basement membrane assembly1144.0×0.023PXDNL
establishment of protein localization to organelle1144.0×0.023LAMP3
response to interferon-alpha1129.6×0.025LAMP3
neutrophil homeostasis1117.8×0.027TSPAN9

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
MiltefosineApproved (phase 4)

11 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
FluconazolePhase 3
ImiquimodPhase 3
Meglumine AntimonatePhase 3
Nitric OxidePhase 3
ParomomycinPhase 3
ANTIMONY CATION (5+)Phase 2
AntimonyPhase 2
GentamicinPhase 2
PentoxifyllinePhase 2
SargramostimPhase 2
TofacitinibPhase 2

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 4 · Undrugged: 11

Druggability breadth: 6 of 15 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
S100BPENTAMIDINE
CALCRPRAMLINTIDE

Top cohort targets by molecule count

SymbolMoleculesMax phase
CALCR34
S100B14
TCF412
SERPINB1012
STX700
LAMP300
CRLF300
CHKB00
DYM00
TSPAN900

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
PENTAMIDINE4S100B
PRAMLINTIDE4CALCR
CALCITONIN SALMON4CALCR
CAGRILINTIDE3CALCR
SALINOMYCIN2TCF4
MOLIBRESIB2SERPINB10

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
CALCR34Binding:24, Functional:10
TCF431Binding:31
CHKB11Binding:11
S100B6Binding:6
SERPINB106Binding:6
PPP6R12Binding:2

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
TCF47.6.2.3ABC-type glutathione-S-conjugate transporter
CHKB2.7.1.32choline kinase
PXDNL1.11.1.7peroxidase

Pharmacogenomics

Cohort genes with a PharmGKB record: 15; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

6 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
PENTAMIDINE4S100B
PRAMLINTIDE4CALCR
CALCITONIN SALMON4CALCR
CAGRILINTIDE3CALCR
SALINOMYCIN2TCF4
MOLIBRESIB2SERPINB10

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)2S100B, CALCR
BPhased (≥1) drug, not yet approved2TCF4, SERPINB10
CDruggable family + PDB, no drug1CHKB
DDruggable family + AlphaFold only, no drug2CRLF3, PXDNL
EDifficult family or no structure, no drug8STX7, LAMP3, DYM, TSPAN9, ZNF385D, KRT80, PPP6R1, MAPK8IP2

Undrugged target profiles

11 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
STX70—
LAMP30—
CRLF30—
CHKB11—
DYM0—
TSPAN90—
ZNF385D0—
PXDNL0—
KRT800—
PPP6R12—
MAPK8IP20—

Clinical trials & evidence

Clinical trials

Clinical trials: 52.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE219
Not specified11
PHASE310
PHASE2/PHASE34
PHASE43
PHASE13
PHASE1/PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00317980PHASE4COMPLETEDSafety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
NCT01462500PHASE4COMPLETEDPharmacokinetics of Miltefosine in Children and Adults
NCT01661296PHASE4COMPLETEDEfficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India
NCT00257530PHASE3COMPLETEDImiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
NCT00317629PHASE3TERMINATEDControlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
NCT00351520PHASE3COMPLETEDEfficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
NCT00471705PHASE3COMPLETEDEfficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
NCT00487253PHASE3UNKNOWNOral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia
NCT00606580PHASE3COMPLETEDPhase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
NCT00682656PHASE2/PHASE3TERMINATEDSafety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
NCT01301924PHASE2/PHASE3COMPLETEDComparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
NCT01381055PHASE2/PHASE3COMPLETEDAntimony Plus Pentoxifylline in Cutaneous Leishmaniasis
NCT01464242PHASE2/PHASE3COMPLETEDAdd-on Study of Pentoxifylline in Cutaneous Leishmaniasis
NCT01790659PHASE3COMPLETEDPhase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
NCT01953744PHASE3TERMINATEDHigh Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
NCT03023111PHASE3COMPLETEDMiltefosine and GM-CSF in Cutaneous Leishmaniasis
NCT04340128PHASE3COMPLETEDEfficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
NCT06797544PHASE2RECRUITINGIntralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
NCT06798402PHASE2RECRUITINGCiprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate
NCT06798415PHASE2RECRUITINGIntralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis
NCT00121862PHASE2COMPLETEDStudy to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
NCT00233545PHASE2COMPLETEDMiltefosine to Treat Cutaneous Leishmaniasis in Bolivia
NCT00633009PHASE2COMPLETEDSafety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
NCT00657917PHASE2TERMINATEDTopical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396
NCT00703924PHASE2COMPLETEDTopical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
NCT00840359PHASE2UNKNOWNStudy of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis
NCT00884377PHASE2COMPLETEDLocal Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis
NCT00973128PHASE2COMPLETEDReduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
NCT01011309PHASE2COMPLETEDA Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
NCT01050907PHASE2COMPLETEDMiltefosine to Treat Mucocutaneous Leishmaniasis
NCT01300975PHASE2COMPLETEDIntralesional Antimony for Bolivian Cutaneous Leishmaniasis
NCT01380301PHASE2TERMINATEDTreatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
NCT01380314PHASE2COMPLETEDOral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
NCT01494350PHASE2TERMINATEDWR 279,396 Open Label Treatment Protocol in Tunisia
NCT01845727PHASE1/PHASE2COMPLETEDTopical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia
NCT01988909PHASE2COMPLETEDWR 279,396 for the Treatment of Cutaneous Leishmaniasis
NCT02687971PHASE2COMPLETEDThermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨
NCT07149753PHASE1NOT_YET_RECRUITINGPilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
NCT00001906PHASE1COMPLETEDSafety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants
NCT00121849PHASE1COMPLETEDSafety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PAROMOMYCIN49
MILTEFOSINE48
SODIUM STIBOGLUCONATE43
IMIQUIMOD42
PENTOXIFYLLINE42
FLUCONAZOLE41
MEGLUMINE ANTIMONATE38
ANTIMONY32
ANTIMONY CATION (5+)31
CHEMBL453755907
CHEMBL45449407
CHEMBL207969905
CHEMBL373628304
CHEMBL375436404
CHEMBL407508902
CHEMBL474526702
CHEMBL527393202
CHEMBL444426001

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 75

This page pulls from 75 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergardgenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptuberonufeatureumlsuniprot